From Drug Complexity to Delivery Strategy

As pharmaceutical innovation has accelerated over the past several decades, one reality has remained constant: the more advanced the molecule, the more sophisticated the delivery solution must be. Biologic drugs, ranging from peptides and monoclonal antibodies to novel protein-based therapies, cannot be administered orally. They require precise, parenteral delivery, and increasingly, subcutaneous injection has become the preferred route due to its patient-friendliness and clinical flexibility.

This shift has transformed the landscape for drug delivery devices. What once were basic, functional tools, often treated as secondary packaging, are now central components of pharmaceutical product strategies. Self-injection systems, in particular, enable decentralised care, improve adherence, and help differentiate therapies in increasingly competitive markets.

Ypsomed recognised this transformation early. With decades of experience in injection systems and a focus on patient-centric subcutaneous delivery, the company has developed platforms and capabilities that meet the evolving needs of both drug developers and end users. Today, as the requirements for combination products grow more complex, the delivery device is no longer a technical afterthought – it’s a critical success factor. Designing for success means building with flexibility, scalability, and strategic alignment from day one.